Methylene Blue Isn’t Just a Supplement

Over the past several months, I have seen a noticeable increase in pilots arriving for FAA medical examinations who report taking methylene blue as a supplement. Most are not using it for methemoglobinemia or another recognized clinical indication. They are taking it for energy, focus, “mitochondrial support,” memory, longevity, or general performance optimization—often after hearing about it on a podcast or social-media channel.

That creates an important aviation-medical problem. Methylene blue use is disqualifying and is not permitted by the FAA while flying. A pilot taking methylene blue must stop flying, regardless of whether the product was prescribed, compounded, or sold as a supplement. Calling it a supplement does not make it a benign vitamin or create an FAA exception. It is a biologically active drug with dose-dependent effects on cellular metabolism, clinically important drug interactions, a boxed warning for serotonin syndrome, and the potential to cause neurologic, cardiovascular, visual, and hematologic adverse effects. The medical condition for which someone is taking it may also be independently disqualifying or require FAA review.

The short version for pilots

The FDA-approved methylene blue product is an intravenous prescription drug for acquired methemoglobinemia—not an oral wellness or nootropic supplement.
Evidence for improved cognition, energy, longevity, or performance in healthy people is preliminary and nowhere near the quality needed to establish routine benefit or long-term safety.
Methylene blue is a clinically meaningful monoamine oxidase-A inhibitor and can cause serious or fatal serotonin syndrome when combined with serotonergic medications and some opioids.
Methylene blue use is FAA-disqualifying. Pilots are not permitted to fly while taking it, including when it is marketed as an over-the-counter supplement or nootropic.
The FAA does not maintain a universal list of “approved” medications. It evaluates the medication, adverse effects, interactions, dose, reason for use, and underlying condition.
After discontinuing it, do not self-clear based on feeling well or counting half-lives. Contact your AME for guidance before returning to flight.

From Blue Dye to One of the First Synthetic Medicines

Methylene blue—also called methylthioninium chloride—was synthesized by German chemist Heinrich Caro in 1876 as a textile dye. Its intense color soon made it useful in microscopy. Robert Koch used it as a biological stain, and Paul Ehrlich recognized that chemical dyes could selectively bind to microorganisms and tissues.

In 1891, Ehrlich and Paul Guttmann reported treating malaria with methylene blue. That work helped establish the concept of a chemical agent selectively targeting disease and earned methylene blue a place in history as one of the earliest synthetic drugs. It later became a laboratory stain, a surgical marker, an antimalarial, an antidote, and a tool in several areas of medicine.

This history is genuinely fascinating, but age and versatility are not the same as proof that a medication is safe or effective for every modern use. Digitalis, lithium, and anesthetic gases also have long medical histories. Each remains useful only when the indication, dose, product quality, monitoring, and patient are appropriate.

What Is Methylene Blue Legitimately Used For?

The FDA-approved indication for prescription methylene blue injection is acquired methemoglobinemia. In methemoglobinemia, iron within hemoglobin is oxidized from its normal ferrous state (Fe²⁺) to a ferric state (Fe³⁺). Ferric hemoglobin cannot carry oxygen normally, so a patient may appear cyanotic and develop headache, fatigue, shortness of breath, confusion, arrhythmia, seizure, coma, or death as the methemoglobin level rises.

At an appropriate dose, methylene blue acts as an electron carrier. Through an NADPH-dependent pathway, it is reduced to leukomethylene blue, which helps convert methemoglobin back toward functional hemoglobin. In the right emergency, it can be lifesaving.

Clinicians also use methylene blue for several off-label or procedural purposes, including selected cases of vasoplegic syndrome, ifosfamide-associated encephalopathy, and tissue or anatomic marking during procedures. It has been studied in malaria, neurodegenerative disease, mood disorders, shock, and other conditions. “Studied” or “used off-label,” however, does not mean FDA-approved, established for routine use, or aeromedically acceptable.

How Did It Become a Supplement?

The modern supplement trend grew from legitimate laboratory observations. Methylene blue can participate in redox reactions and, at low concentrations, may shuttle electrons within mitochondria. Preclinical studies have reported effects on cytochrome oxidase activity, oxidative stress, cellular respiration, and memory-related pathways. Small human studies have explored effects on fear-extinction memory, brain activity, and certain neurologic diseases.

Those findings created an appealing story: if mitochondria produce cellular energy, and methylene blue can influence mitochondrial electron flow, perhaps a small daily dose will improve energy, cognition, or longevity. That narrative moved quickly from bench science to podcasts, online clinics, compounding pharmacies, and direct-to-consumer products.

The problem is that the marketing has moved much faster than the clinical evidence.

What Does the Evidence Actually Show?

There is meaningful scientific interest in methylene blue, but there is not high-quality evidence establishing that chronic oral methylene blue improves cognition, focus, energy, athletic performance, or longevity in healthy adults. Much of the enthusiasm comes from cell studies, animal models, mechanistic papers, uncontrolled observations, or small studies designed to answer narrow research questions.

For example, a small randomized study in adults with claustrophobia evaluated a single post-training dose and aspects of fear-extinction memory. Other imaging research has examined acute changes in cerebral metabolism or functional connectivity. Trials involving Alzheimer disease or other neurologic conditions address diseased populations and often involve related compounds, specialized formulations, or outcomes that cannot simply be extrapolated to a healthy pilot taking an internet supplement every morning.

Important questions remain unanswered:

What dose, if any, provides a meaningful benefit to a healthy person?
Does any short-term laboratory effect translate into safer or better real-world performance?
What are the risks of daily use over months or years?
How much do oral formulations vary in purity, concentration, and absorption?
Which medication combinations or genetic factors create unacceptable risk?
Does repeated exposure produce accumulation or dose-dependent toxicity?

Until adequately powered, well-controlled trials answer those questions, methylene blue should not be presented as a proven nootropic or longevity therapy.

Pharmacodynamics: Why the Dose and Context Matter

Methylene blue is a classic example of a drug with dose-dependent and sometimes opposing effects. At lower concentrations, its reversible redox cycling may facilitate electron transfer. At higher concentrations, it can become pro-oxidant, interfere with normal cellular processes, and worsen rather than improve methemoglobinemia.

It also inhibits monoamine oxidase-A (MAO-A), the enzyme involved in metabolizing serotonin and other monoamines. This is not a theoretical supplement interaction. The FDA-approved label carries a boxed warning because methylene blue combined with serotonergic medications or certain opioids can precipitate serious or fatal serotonin syndrome.

Potentially relevant combinations include many SSRIs, SNRIs, tricyclic antidepressants, other MAO inhibitors, some migraine medications, dextromethorphan-containing cough products, and certain opioids. A pilot may not realize that a “mitochondrial supplement” is pharmacologically colliding with a prescribed antidepressant or common over-the-counter product.

Other important risks include:

Hemolytic anemia in people with glucose-6-phosphate dehydrogenase (G6PD) deficiency. The approved product is contraindicated in known G6PD deficiency.
Neurologic effects such as headache, dizziness, confusion, agitation, myoclonus, and seizure-like activity.
Gastrointestinal effects including nausea, vomiting, abdominal discomfort, and diarrhea.
Cardiovascular effects including changes in blood pressure and heart rate.
Visual and monitoring interference. Its intense color can interfere with pulse oximetry and certain laboratory or optical measurements.
Blue or green discoloration of urine, stool, saliva, or skin. This is often harmless by itself but demonstrates that the compound and its metabolites are systemically present.
Pregnancy and fetal risk. The label warns of potential fetal harm.

How Is It Taken, and How Long Does It Stay in the Body?

The FDA-approved product is administered intravenously in a controlled clinical setting for methemoglobinemia. Products marketed for wellness are commonly taken orally as drops, capsules, lozenges, or compounded preparations. These oral supplement uses are not the FDA-approved indication or route, and product quality may vary substantially.

Human studies indicate that methylene blue can be absorbed orally, but the pharmacokinetics of an internet or compounded product cannot be assumed to match the approved intravenous formulation. Concentration, salt form, excipients, purity, dose measurement, food, kidney function, repeated dosing, and other medications may alter exposure.

The FDA-approved intravenous label reports an elimination half-life of approximately 24 hours in humans and notes that about 40% is excreted unchanged in urine. A 24-hour half-life means the body burden is reduced by roughly half every 24 hours under the assumptions of that model—it does not mean the drug is completely gone or that a pilot is automatically safe to fly the next day.

Approximate time after last dose	Estimated amount remaining*
24 hours	50%
48 hours	25%
72 hours	12.5%
About 5 days	About 3%

*This is a simplified illustration based on a 24-hour half-life, not a personalized clearance estimate or an FAA-mandated waiting period. Repeated dosing, renal impairment, dose, formulation, interactions, and individual physiology can change exposure. Pharmacologic or clinical effects may not track perfectly with plasma concentration.

In pharmacology, five half-lives is often used as a rough estimate for eliminating most of a drug. For methylene blue, that would be about five days using the label's average half-life. This is not an FAA clearance rule. A pilot cannot self-clear solely by counting half-lives. Symptoms, adverse effects, interactions, repeated use, the exact product, and the reason for taking it all matter.

Why the FAA Is Concerned

For pilots, the immediate operational answer is clear: methylene blue use is disqualifying, and the FAA does not permit a pilot to fly while taking it. This applies even when the product is purchased without a prescription and labeled as a supplement, nootropic, or wellness product.

The FAA does not publish a comprehensive list of universally acceptable medications. Its medication FAQ explains that pilot performance may be affected by both the underlying medical condition and the medication. That broader policy does not make methylene blue acceptable for flight; it means the pilot's use, adverse effects, interactions, indication, and underlying condition must also be evaluated when determining the path back to flying.

That distinction is especially important with methylene blue:

The drug itself can impair safe performance. Dizziness, confusion, visual effects, blood-pressure changes, agitation, and neurologic toxicity are incompatible with safe flight.
Interactions may be dangerous. MAO-A inhibition and serotonin syndrome are serious concerns, particularly when psychiatric, pain, migraine, or cough medications are also used.
The reason for use may be disqualifying or require review. A pilot taking it for depression, cognitive decline, a neurologic complaint, fatigue, methemoglobinemia, shock, or another medical condition cannot separate the product from the diagnosis or symptom that prompted its use.
“Supplement” is not an aeromedical exemption. FAA Form 8500-8 Item 17.a asks about current prescription and nonprescription medication use. The AME Guide explicitly states that this includes both prescription and nonprescription medication.
Product uncertainty adds risk. A dropper bottle purchased online may not provide pharmaceutical-grade purity, reliable concentration, consistent dosing, or adequate screening for interactions.

Under 14 CFR 61.53, pilots also have an ongoing duty not to act as required flightcrew when they know or have reason to know of a medical condition—or are taking medication or treatment—that would make them unable to meet the requirements for the operation. That responsibility exists between medical examinations, not only on the day an FAA application is completed.

Practical aviation guidance: Do not fly while taking methylene blue. Its use is FAA-disqualifying and is not permitted while exercising pilot privileges, including when it is sold without a prescription as a supplement. After stopping it, speak with your AME before returning to flight; elapsed time alone is not aeromedical clearance. If methylene blue was prescribed for a legitimate medical emergency or condition, follow the treating clinician's instructions and coordinate the diagnosis, treatment, recovery, and return-to-flight plan with your AME.

What Pilots Should Bring to Their AME

If you have used methylene blue, gather the details before contacting your AME:

Exact product name, manufacturer, and a photograph of the label
Concentration and dose—not merely “one dropper”
Route, frequency, start date, last dose, and duration of use
Why you started taking it and who recommended or prescribed it
All prescription drugs, over-the-counter products, and other supplements
Any side effects, including headache, dizziness, mood change, visual symptoms, gastrointestinal symptoms, unusual fatigue, or discoloration
Any diagnosis, symptom, laboratory result, or performance concern that motivated its use

Do not abruptly stop a medically necessary prescribed treatment without speaking to the treating clinician. On the other hand, a self-directed wellness product should not be continued simply because a seller calls the dose “low” or “mitochondrial.” The safest path is coordinated review before flight.

The Bottom Line

Methylene blue is a remarkable compound with an important place in medical history and a legitimate lifesaving role in acquired methemoglobinemia. It is also a potent drug with complex, dose-dependent pharmacology. That is precisely why it should not be casually repackaged as a harmless blue wellness drop.

For pilots, the bottom line is unambiguous: methylene blue use is disqualifying, and pilots may not fly while taking it. The evidence for routine supplementation in healthy people is weak, the interaction profile is consequential, the average half-life is long enough to matter, and the reason for taking it may create additional certification concerns. Purchasing it online or feeling normal does not change its FAA status.

If you are taking—or considering taking—methylene blue, contact Go Flight Medicine before you fly or submit your next FAA medical application. We can review the exact product, indication, medication list, timing, and safest path forward.

References

This article is educational and does not replace individualized medical advice or an FAA certification decision. Medication acceptability and return-to-flight timing depend on the pilot, diagnosis, dose, formulation, co-medications, adverse effects, and applicable FAA review.